Epilepsy Clinical Trials
Here are the 6 most popular medical studies for epilepsy
Corticosteroid
TDCS for Epilepsy
This trial is measuring the electrical fields caused by tDCS in people with implanted electrodes as part of their evaluation for epilepsy surgery, in order to improve mathematical models. The models can then be used to target tDCS to specific brain regions in healthy and sick people. The stimulations used in this trial are not expected to produce any changes in brain function.
Procedure
Noninvasive Imaging for Epilepsy
This trial will compare the sensitivities and specificities of morphometric analysis techniques using MRI images to pre- and postsurgical localization of epileptic foci in patients undergoing presurgical evaluation for medically refractory epilepsy, in order to establish an age-stratified normative imaging database.
Popular filter options for epilepsy trials
Lennox Gastaut Syndrome Clinical Trials
View 86 Lennox Gastaut Syndrome medical studies.
Device
SPEAC System for Seizure Monitoring
This trial will test a device that uses sEMG to monitor for seizures and send alerts. It will be given to Veterans with a history of motor seizures who have upper extremity motor involvement and present with questionable spell characterization. The trial will take place in the home setting.
Soticlestat for Rare Epilepsies
This trial is testing a new drug to see if it is safe and effective when used with other anti-seizure drugs. Participants will take the drug twice a day and visit the clinic every few months. The study will continue as long as the participant benefits from the drug.
Nutrition
Triheptanoin for Glut1 Deficiency Syndrome
This trial will study the effects of C7 supplementation on 45 subjects with G1D who are not receiving any dietary therapy. EEG activity, IQ, language, working memory, processing speed, emotional and behavioral functioning, ataxia, and other neuropsychological and neurological performance indices will be evaluated.
Dravet Syndrome Clinical Trials
View 85 Dravet Syndrome medical studies.
Device
SPEAC System for Seizure Monitoring
This trial will test a device that uses sEMG to monitor for seizures and send alerts. It will be given to Veterans with a history of motor seizures who have upper extremity motor involvement and present with questionable spell characterization. The trial will take place in the home setting.
Soticlestat for Rare Epilepsies
This trial is testing a new drug to see if it is safe and effective when used with other anti-seizure drugs. Participants will take the drug twice a day and visit the clinic every few months. The study will continue as long as the participant benefits from the drug.
Nutrition
Triheptanoin for Glut1 Deficiency Syndrome
This trial will study the effects of C7 supplementation on 45 subjects with G1D who are not receiving any dietary therapy. EEG activity, IQ, language, working memory, processing speed, emotional and behavioral functioning, ataxia, and other neuropsychological and neurological performance indices will be evaluated.
Phase 3 Epilepsy Clinical Trials
View 97 phase 3 epilepsy medical studies.
Responsive Neurostimulation for Generalized Epilepsy
This trial shows that the RNS System for thalamic stimulation is safe and effective for reducing primary generalized seizures in individuals 12 years of age or older with drug-resistant idiopathic generalized epilepsy.
Dietary Intervention
Ketogenic Diet vs Medication for Childhood Absence Epilepsy
This trial is to assess if the modified Atkins diet is a feasible and effective option for new-onset childhood absence epilepsy, as compared to a group of children in which the parents have declined and chose to start anticonvulsant medications.
Epilepsy Clinical Trials With No Placebo
View 97 epilepsy medical studies that do not have a placebo group.
Device
SPEAC System for Seizure Monitoring
This trial will test a device that uses sEMG to monitor for seizures and send alerts. It will be given to Veterans with a history of motor seizures who have upper extremity motor involvement and present with questionable spell characterization. The trial will take place in the home setting.
Soticlestat for Rare Epilepsies
This trial is testing a new drug to see if it is safe and effective when used with other anti-seizure drugs. Participants will take the drug twice a day and visit the clinic every few months. The study will continue as long as the participant benefits from the drug.
Nutrition
Triheptanoin for Glut1 Deficiency Syndrome
This trial will study the effects of C7 supplementation on 45 subjects with G1D who are not receiving any dietary therapy. EEG activity, IQ, language, working memory, processing speed, emotional and behavioral functioning, ataxia, and other neuropsychological and neurological performance indices will be evaluated.
View More Epilepsy Trials
See another 76 medical studies focused on epilepsy.
Frequently Asked Questions
Introduction to epilepsy
What are the top hospitals conducting epilepsy research?
When it comes to advancing the understanding and treatment of epilepsy, several hospitals are leading the charge with their innovative clinical trials. One such institution is the Northeast Regional Epilepsy Group in Hackensack, which currently has eight active epilepsy trials underway. Over the years, they have conducted a total of 19 trials since recording their first one in 2008. Similarly dedicated to exploring new possibilities for epilepsy treatment is the Mid-Atlantic Epilepsy and Sleep Center in Bethesda, with eight ongoing trials and an impressive history of 25 completed ones dating back to their initial trial in 2005.
In Boston, Massachusetts General Hospital stands at the forefront of epilepsy research as well. With eight active clinical trials focused on this condition and a notable record of conducting 19 previous studies since their first recorded trial in 2005, this esteemed hospital continues to make significant contributions towards improving outcomes for those living with epilepsy.
Further west, Mayo Clinic located in Rochester takes pride in its seven active epilepsy trials. Having initiated its pioneering investigation into this neurological disorder also during that time frame itself adds up achievements through twenty-eight accomplished experiments over time presents them as highly reputable medical establishment within these realms.
Last but not least we find ourselves at University of California San Francisco where six current epileptic-focused investigations are being carried out; despite having registered relatively late entry compared to other institutions -only just over a decade ago-, they too hold commendable track record holding twelve successful past probes from day one till now established themselves as worthy contenders contributing significantly towards enhancing our knowledge about Epilepsy
These esteemed hospitals not only provide hope for individuals affected by epilepsy but also serve as beacons lighting up paths toward improved treatments and potential cures. Through rigorous scientific inquiry and dedication from top researchers across different locations nationwide proves that collective efforts can indeed bring us closer to better management options making life more manageable for patients facing seizures related challenges- thus truly exemplifying power amid unity
Which are the best cities for epilepsy clinical trials?
When it comes to epilepsy clinical trials, several cities have emerged as leaders in research and development. New york City boasts 31 active trials, exploring treatments like Lorcaserin, Soticlestat, and Methylphenidate. Boston follows closely with 20 ongoing studies focused on innovative approaches such as Soticlestat, the STARSTIM device, and Vatiquinone. Miami also shows promising progress with 19 active trials investigating treatments like Lacosamide intravenous and Cenobamate. Rochester in Minnesota and Houston in Texas both have 18 active trials each studying various potential treatments for epilepsy patients. These cities offer individuals living with epilepsy opportunities to participate in cutting-edge clinical trials that pave the way for advancements in care for this condition.
Which are the top treatments for epilepsy being explored in clinical trials?
Exciting advancements are being made in the search for effective epilepsy treatments, with several options shining brightly in ongoing clinical trials. Among these top contenders is Speech Tasks, currently under investigation in two active trials dedicated to epilepsy research since its listing in 2015. Equally promising is brivaracetam, which has caught the attention of researchers with its involvement in 23 all-time epilepsy trials and two currently underway. Additionally, cenobamate and LP352 have each earned their place on this list through their participation in two active and all-time epilepsy studies. These groundbreaking treatments offer hope for a brighter future for individuals living with epilepsy worldwide.
What are the most recent clinical trials for epilepsy?
Promising advancements are being made in the realm of epilepsy treatment through recent clinical trials. One notable trial focuses on the use of methylphenidate, a medication commonly used for attention deficit hyperactivity disorder (ADHD), to manage epilepsy. This phase 4 study aims to assess its effectiveness and safety in individuals with epilepsy. Additionally, preliminary safety trials involving various phases (1 and 2) have been conducted to evaluate new approaches for managing this condition. Among them is LP352, an investigational drug being explored in a phase 2 trial with encouraging results thus far. Similarly, another phase 2 trial named Condition A has shown potential as an alternative therapy for people living with epilepsy. Furthermore, research into ketamine hydrochloride's efficacy in treating seizures continues to progress through a comprehensive phase 2 study. These ongoing efforts hold promise for improving the lives of those affected by epilepsy.
What epilepsy clinical trials were recently completed?
Recent advancements in epilepsy research have seen the completion of several noteworthy clinical trials. In April 2021, Neurocrine Biosciences completed a trial investigating NBI-827104 as a potential treatment option. Similarly, Children's Hospital Medical Center, Cincinnati concluded their trial on TAVT-18 (sirolimus) in September 2020. Additionally, Marinus Pharmaceuticals made significant strides with their Ganaxolone trial which was completed in May 2019. Finally, Seattle Children's Hospital wrapped up their ABI-009 study back in July 2018. These trials represent important milestones and offer hope for improved therapeutic options to help individuals living with epilepsy manage this challenging condition more effectively.